NVRO250117C5000
- 0.10
- +0.05+100.00%
Nevro Newsroom
CCORF Maintains Nevro(NVRO.US) With Hold Rating, Cuts Target Price to $4
Truist Financial Maintains Nevro(NVRO.US) With Hold Rating
Nevro Corp: Balancing Short-Term Gains and Long-Term Uncertainties With a Hold Rating
RBC Capital Maintains Nevro(NVRO.US) With Hold Rating, Maintains Target Price $7
RBC Capital Remains a Hold on Nevro Corp (NVRO)
Truist Financial Maintains Nevro(NVRO.US) With Hold Rating, Cuts Target Price to $4.7
Mizuho Securities Maintains Nevro(NVRO.US) With Hold Rating, Announces Target Price $6
Nevro Is Maintained at Neutral by Citigroup
Nevro Is Maintained at Equal-Weight by Wells Fargo
Nevro Analyst Ratings
Citi Maintains Nevro(NVRO.US) With Hold Rating, Cuts Target Price to $5
Canaccord Genuity Maintains Hold on Nevro, Lowers Price Target to $4
Wells Fargo Reinstates Equal-Weight on Nevro, Announces $5 Price Target
Wells Fargo Upgrades Nevro(NVRO.US) to Hold Rating, Cuts Target Price to $5
Nevro Cut to Underweight From Equal-Weight by Morgan Stanley
Nevro Analyst Ratings
Morgan Stanley Downgrades Nevro(NVRO.US) to Sell Rating, Cuts Target Price to $4
Truist Financial Maintains Nevro(NVRO.US) With Hold Rating, Raises Target Price to $7
A Quick Look at Today's Ratings for Nevro(NVRO.US), With a Forecast Between $7 to $7
Analysts Have Conflicting Sentiments on These Healthcare Companies: Quanterix (QTRX), Nevro Corp (NVRO) and Tempest Therapeutics (TPST)